Matching trials
2,411 results
- NB-001 in Children and Adolescents With 22q11 Deletion Syndrome: Complete Statistical AnalysisIndependent statistical analysis of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05290493).
- NEAT-HFpEFIndependent statistical analysis of the randomized crossover NEAT-HFpEF phase 2 trial evaluating isosorbide mononitrate versus placebo for daily activity in heart failure.
- Nebulized Hypertonic Saline for Mechanically Ventilated Children: Complete Statistical AnalysisIndependent statistical analysis of Nebulized Hypertonic Saline for Mechanically Ventilated Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01945944).
- Neo TrioIndependent statistical analysis of Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients: Complete Statistical AnalysisIndependent statistical analysis of Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04512430).
- Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03747120).
- Neoadjuvant Immunotherapy in Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Immunotherapy in Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04434560).
- Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04869137).
- Neoadjuvant Pazopanib in Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Pazopanib in Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01361113).
- Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2: primary endpoint results, effect estimate…
- Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00828308).
- NeohttpIndependent statistical analysis of Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02345772).
- NEOMUNIndependent statistical analysis of Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03197467).
- NEPALIndependent statistical analysis of A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Nesiritide Use Following Cardiac Surgery in Infants: Complete Statistical AnalysisIndependent statistical analysis of Nesiritide Use Following Cardiac Surgery in Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00281671).
- NEST-1Independent statistical analysis of Combination Immunotherapy in Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05571293).
- Neural Substrates in Nicotine Withdrawal: Complete Statistical AnalysisIndependent statistical analysis of Neural Substrates in Nicotine Withdrawal: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01001520).
- NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis: Complete Statistical AnalysisIndependent statistical analysis of NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04638673).
- Neuromodulation Techniques After SCI: Complete Statistical AnalysisIndependent statistical analysis of Neuromodulation Techniques After SCI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04241250).
- Neuroprotection With Riluzole Patients With Early Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Neuroprotection With Riluzole Patients With Early Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00501943).
- Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain: Complete Statistical AnalysisIndependent statistical analysis of Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Neurosteroids for Treatment of PTSD in Veterans: Complete Statistical AnalysisIndependent statistical analysis of Neurosteroids for Treatment of PTSD in Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03799562).
- Neurotropin to Treat Chronic Neuropathic Pain: Complete Statistical AnalysisIndependent statistical analysis of Neurotropin to Treat Chronic Neuropathic Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006289).
- New Treatment for Alcohol and Nicotine Dependence: Complete Statistical AnalysisIndependent statistical analysis of New Treatment for Alcohol and Nicotine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01182766).
- NewHopeIndependent statistical analysis of Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NEXUSIndependent statistical analysis of Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- NIA-SCOREIndependent statistical analysis of NeuroCognition After Carotid Recanalization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04219774).
- NICHEIndependent statistical analysis of NICHE (NCT03026140), a randomized phase 2 trial evaluating neoadjuvant immune checkpoint inhibition and novel immuno-oncology combinations in early-stage colon cancer.
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: Complete Statistical AnalysisIndependent statistical analysis of Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02389764).
- Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Niraparib + Dostarlimab + RT in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab + RT in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04409002).
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04584255).
- NIRVANAIndependent statistical analysis of A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause: primary endpoint results, effect estimate with confidence…
- NIRVANA-1Independent statistical analysis of the randomized phase 2 NIRVANA-1 trial evaluating niraparib with bevacizumab after complete cytoreduction in patients with ovarian cancer, including its progression-free survival endpoint and planned statistical interpretation.
- Nitrite Infusion in Islet Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Nitrite Infusion in Islet Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03544242).
- Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03693846).
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): Complete Statistical AnalysisIndependent statistical analysis of NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): primary endpoint results, effect estimate with…